Holders — by stockHoldings — by fund
Jones Hill Capital LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0002102314
$589.2M
disclosed book value
33
positions
11.9%
largest position share
Positions, as of 2026-09-30
top 33 of 33 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | BMRNBIOMARIN PHARMACEUTICAL INC | 1.2M | $70.3M | 11.9% |
| 2 | BCRXBIOCRYST PHARMACEUTICALS INC | 7.1M | $59.0M | 10% |
| 3 | TVTXTRAVERE THERAPEUTICS INC | 959,634 | $56.5M | 9.6% |
| 4 | INDVINDIVIOR PHARMACEUTICALS INC | 1.5M | $54.7M | 9.3% |
| 5 | PHVSPHARVARIS N V | 987,637 | $31.3M | 5.3% |
| 6 | CELCCELCUITY INC | 382,901 | $30.4M | 5.2% |
| 7 | IONSIONIS PHARMACEUTICALS INC | 599,826 | $26.8M | 4.5% |
| 8 | SUPNSUPERNUS PHARMACEUTICALS | 601,685 | $25.9M | 4.4% |
| 9 | NUVBNUVATION BIO INC | 4.5M | $25.1M | 4.3% |
| 10 | VERAVERA THERAPEUTICS INC | 652,218 | $21.1M | 3.6% |
| 11 | TRVITREVI THERAPEUTICS INC | 1.4M | $20.7M | 3.5% |
| 12 | BCAXBICARA THERAPEUTICS INC | 1.1M | $19.8M | 3.4% |
| 13 | RLMDRELMADA THERAPEUTICS INC | 5.2M | $19.7M | 3.4% |
| 14 | ABVXABIVAX SA | 142,558 | $14.1M | 2.4% |
| 15 | ACRSACLARIS THERAPEUTICS INC | 2.5M | $13.2M | 2.2% |
| 16 | INSMINSMED INC | 106,528 | $12.2M | 2.1% |
| 17 | NBIXNEUROCRINE BIOSCIENCES INC | 83,426 | $11.8M | 2% |
| 18 | IMCRIMMUNOCORE HLDGS PLC | 384,278 | $11.6M | 2% |
| 19 | ERASERASCA INC | 610,118 | $8.9M | 1.5% |
| 20 | CAPRCAPRICOR THERAPEUTICS INC | 892,532 | $8.5M | 1.4% |
| 21 | DNTHDIANTHUS THERAPEUTICS INC | 80,017 | $7.0M | 1.2% |
| 22 | NGNENEUROGENE INC | 217,700 | $6.1M | 1% |
| 23 | CRBPCORBUS PHARMACEUTICALS HLDGS | 886,428 | $6.0M | 1% |
| 24 | TNXPTONIX PHARMACEUTICALS HLDG C | 563,739 | $5.5M | 0.9% |
| 25 | SGMTSAGIMET BIOSCIENCES INC | 502,587 | $5.0M | 0.8% |
| 26 | DYNDYNE THERAPEUTICS INC | 300,900 | $4.8M | 0.8% |
| 27 | AVLNAVALYN PHARMACEUTICALS INC | 126,744 | $3.6M | 0.6% |
| 28 | ATTOATTOVIA THERAPEUTICS INC | 182,295 | $3.1M | 0.5% |
| 29 | PHATPHATHOM PHARMACEUTICALS INC | 276,830 | $2.0M | 0.3% |
| 30 | LXEOLEXEO THERAPEUTICS INC | 593,737 | $2.0M | 0.3% |
| 31 | OLMAOLEMA PHARMACEUTICALS INC | 206,397 | $1.8M | 0.3% |
| 32 | TENXTENAX THERAPEUTICS INC | 122,169 | $230,899 | 0% |
| 33 | ALVOALVOTECH | 26,700 | $154,860 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.